{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:07:46Z","timestamp":1791216466203,"version":"4.1.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T00:00:00Z","timestamp":1654128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM201911010"],"award-info":[{"award-number":["SZSM201911010"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Mucinous appendiceal adenocarcinoma (MAA) is a rare, heterogeneous disease. Patients with unrespectable mucinous appendiceal adenocarcinoma presenting with peritoneal spread are treated by intraperitoneal chemotherapy, hyperthermic intraperitoneal chemotherapy, systemic chemotherapy, or targeted therapy. However, there are no guidelines for efficacious drugs against mucinous appendiceal adenocarcinoma. Therefore, relevant high-fidelity models should be investigated to identify effective drugs for individual therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Surgical tumor specimens were obtained from a mucinous appendiceal adenocarcinoma patient. The tissue was digested and organoid culture was established. H&amp;amp;E and immunohistochemistry staining as well as DNA sequencing was performed on tissue and organoid. The pathological characteristics and gene mutations of the organoid were compared to those of the original tumor. Drug sensitivity tests were performed on organoid and the patient clinical responds to chemotherapy and targeted therapy was compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Organoids were successfully established and stably passaged. Pathological characteristics of organoids including H&amp;amp;E staining and expression of protein markers (CK20, CDX-2, STAB2, CD7, PAX8) were consistent to those of the original tumor. Moreover, the organoids carried the same gene mutations as the primary tumor. Sensitivity of the organoids to chemotherapeutic drugs and tyrosine kinase inhibitors included: 5-FU (IC<jats:sub>50<\/jats:sub> 43.95 \u03bcM), Oxaliplatin (IC<jats:sub>50<\/jats:sub> 23.49 \u03bcM), SN38 (IC<jats:sub>50<\/jats:sub> 1.02 \u03bcM), Apatinib (IC<jats:sub>50<\/jats:sub> 0.10 \u03bcM), Dasatinib (IC<jats:sub>50<\/jats:sub> 2.27 \u03bcM), Docetaxel (IC<jats:sub>50<\/jats:sub> 5.26 \u03bcM), Regorafenib (IC<jats:sub>50<\/jats:sub> 18.90 \u03bcM), and Everolimus (IC<jats:sub>50<\/jats:sub> 9.20 \u03bcM). The sensitivities of organoid to these drugs were comparable to those of the patient's clinical responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The mucinous appendiceal adenocarcinoma organoid model which retained the characteristics of the primary tumor was successfully established. Combined organoid-based drug screening and high throughput sequencing provided a promising way for mucinous appendiceal adenocarcinoma treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.829033","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T05:54:57Z","timestamp":1654149297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Organoids From Mucinous Appendiceal Adenocarcinomas as High-Fidelity Models for Individual Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Guangyao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1055\/s-0035-1564433","article-title":"Management of Appendix Cancer","volume":"28","author":"Kelly","year":"2015","journal-title":"Clin Colon Rectal Surg"},{"key":"B3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.5152\/tjg.2018.17605","article-title":"Evaluation of appendiceal mucinous neoplasms with a new classification system and literature review","volume":"29","author":"Gundogar","year":"2018","journal-title":"Turk J Gastroenterol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1097\/COC.0000000000000210","article-title":"Incidence and survival of appendiceal mucinous neoplasms: a SEER analysis","volume":"40","author":"Shaib","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1634\/theoncologist.2017-0081","article-title":"Appendiceal mucinous neoplasms: diagnosis and management","volume":"22","author":"Shaib","year":"2017","journal-title":"Oncologist"},{"key":"B6","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/jso.23547","article-title":"Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"109","author":"Blackham","year":"2014","journal-title":"J Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.6004\/jnccn.2021.0012","article-title":"Colon cancer, Version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Benson","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"B8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/jso.25599","article-title":"Systemic chemotherapy and survival in patients with metastatic low-grade appendiceal mucinous adenocarcinoma","volume":"120","author":"Lu","year":"2019","journal-title":"J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/cncr.24715","article-title":"Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience","volume":"116","author":"Shapiro","year":"2010","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/gm559","article-title":"Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin","volume":"6","author":"Alakus","year":"2014","journal-title":"Genome Medicine."},{"key":"B11","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2015.03.053","article-title":"Prospective derivation of a living organoid biobank of colorectal cancer patients","volume":"161","author":"van de Wetering","year":"2015","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1126\/science.1254721","article-title":"Patient-derived models of acquired resistance can identify effective drug combinations for cancer","volume":"346","author":"Crystal","year":"2014","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"eaay2574","DOI":"10.1126\/scitranslmed.aay2574","article-title":"Patient-derived organoids can predict response to Chemotherapy in metastatic colorectal cancer patients","volume":"11","author":"Ooft","year":"2019","journal-title":"Sci Transl Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1245\/s10434-018-7008-2","article-title":"Appendiceal cancer patient-specific tumor organoid model for predicting chemotherapy efficacy prior to initiation of treatment: a feasibility study","volume":"26","author":"Votanopoulos","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eu J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/jclinpath-2011-200407","article-title":"Mucinous tumours of the ovary\u2013primary and metastatic","volume":"65","author":"Heatley","year":"2012","journal-title":"J Clin Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s13104-019-4816-9","article-title":"The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm","volume":"12","author":"Aldaoud","year":"2019","journal-title":"BMC Res Notes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1245\/s10434-020-08210-5","article-title":"Prognostic molecular classification of appendiceal mucinous neoplasms treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"27","author":"Su","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1245\/s10434-019-07879-7","article-title":"Molecular and genetic markers in appendiceal mucinous tumors: a systematic review","volume":"27","author":"Stein","year":"2020","journal-title":"ann Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10786","DOI":"10.18632\/oncotarget.3198","article-title":"Global gene expression in pseudomyxoma peritonei, with parallel development of two immortalized cell lines","volume":"6","author":"Roberts","year":"2015","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.trsl.2020.10.005","article-title":"Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer","volume":"229","author":"Dilly","year":"2021","journal-title":"Translat Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-019-0255-2","article-title":"Organoid models of gastrointestinal cancers in basic and translational research","volume":"17","author":"Lau","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1245\/s10434-007-9699-7","article-title":"VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon","volume":"15","author":"Logan-Collins","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"164","DOI":"10.21037\/jgo.2017.01.14","article-title":"Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis","volume":"8","author":"Borazanci","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s00432-019-03004-z","article-title":"Malignant ascites-derived organoid (MADO) cultures for gastric cancer in vitro modelling and drug screening","volume":"145","author":"Li","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drup.2015.05.003","article-title":"Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy","volume":"20","author":"De Mattia","year":"2015","journal-title":"Drug Resist Updat"},{"key":"B29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","article-title":"Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis","volume":"589","author":"Pastushenko","year":"2021","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41416-019-0616-1","article-title":"Patient-derived organoids as a potential model to predict response to PD-1\/PD-L1 checkpoint inhibitors","volume":"121","author":"Scognamiglio","year":"2019","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.829033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T05:55:02Z","timestamp":1654149302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.829033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,2]]},"references-count":30,"alternative-id":["10.3389\/fmed.2022.829033"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.829033","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,2]]},"article-number":"829033"}}